Table 3. Biodistribution Data of 89Zr-DFO-T/N-trastuzumab versus Time in Mice Bearing Bilateral s.c. BT-474 (HER2-positive) and MDA-MB-468 (HER2-negative) Xenografts (n = 4 for Each Time Point).
| 6 h | 24 h | 48 h | 72 h | 96 h | 120 h | |
|---|---|---|---|---|---|---|
| blood | 42.2 ± 8.8 | 37.4 ± 3.4 | 24.1 ± 6.1 | 24.1 ± 8.2 | 20.2 ± 2.1 | 18.2 ± 3.3 |
| HER2+ tumor | 22.9 ± 6.6 | 48.6 ± 6.9 | 64.0 ± 6.8 | 75.1 ± 7.6 | 72.2 ± 7.9 | 69.8 ± 3.9 |
| HER2- tumor | 11.2 ± 5.0 | 13.4 ± 4.1 | 14.5 ± 8.8 | 16.8 ± 2.7 | 16.7 ± 6.8 | 17.6 ± 1.7 |
| heart | 24.1 ± 5.7 | 17.7 ± 6.9 | 6.0 ± 3.2 | 9.6 ± 3.8 | 8.5 ± 3.2 | 10.4 ± 0.9 |
| lungs | 15.5 ± 2.4 | 15.8 ± 5.4 | 10.5 ± 4.6 | 11.9 ± 4.8 | 13.8 ± 8.1 | 12.9 ± 3.2 |
| liver | 24.2 ± 5.0 | 17.6 ± 4.7 | 16.0 ± 6.5 | 15.8 ± 1.4 | 12.8 ± 2.7 | 13.5 ± 7.3 |
| spleen | 11.3 ± 1.2 | 14.2 ± 5.3 | 15.0 ± 5.1 | 14.9 ± 5.2 | 12.6 ± 6.5 | 10.8 ± 5.3 |
| stomach | 6.7 ± 1.4 | 3.1 ± 0.2 | 2.5 ± 0.7 | 2.0 ± 0.5 | 1.9 ± 0.4 | 1.8 ± 0.3 |
| small intestine | 8.4 ± 1.7 | 6.3 ± 0.3 | 7.9 ± 2.9 | 4.8 ± 1.1 | 3.8 ± 0.9 | 4.4 ± 0.8 |
| large intestine | 4.5 ± 1.0 | 2.1 ± 0.6 | 1.7 ± 0.2 | 2.3 ± 0.9 | 1.0 ± 0.3 | 1.4 ± 0.5 |
| kidney | 15.9 ± 5.4 | 13.3 ± 1.2 | 7.0 ± 1.3 | 11.6 ± 2.6 | 10.2 ± 0.3 | 8.7 ± 2.9 |
| muscle | 2.2 ± 0.6 | 2.3 ± 0.2 | 1.6 ± 0.5 | 2.2 ± 0.4 | 2.2 ± 0.2 | 2.5 ± 0.2 |
| bone | 12.1 ± 0.8 | 13.2 ± 2.4 | 14.6 ± 3.8 | 15.2 ± 1.9 | 14.7 ± 3.1 | 15.1 ± 1.5 |